A Phase 1 / 2, Open Label, Study of Amivantamab (JNJ-61186372) Among Participants with Advanced NSCLC Harboring ALK, ROS1, and RET Gene Fusions in Combination with Tyrosine Kinase Inhibitors
![](https://researchstudies.cuanschutz.edu/Content/images/study-category-images/cancer.jpg)
Details
Age
Adult
Locations
Outpatient CTRC
University of Colorado Hospital
University of Michigan
University of Michigan Comprehensive Cancer Center
Principal Investigator
![Photograph of Tejas Patil](https://som.ucdenver.edu/FIMS/Content/faculty/24489/CU-Doctors-24489.jpg)
Tejas Patil
Study ID
Protocol Number: 22-1450
More information available at ClinicalTrials.gov: NCT05845671
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers